Ensuring drug product–blister film compatibility means confirming that the plastic or foil materials used in a blister pack neither degrade the drug nor allow unacceptable interactions. In other words, the film must protect the drug without affecting its quality. The four key risks to check are migration (chemicals moving from film into the drug), sorption (drug ingredients absorbing into the film), static charge, and friction. Each of these can undermine stability, potency or manufacturing yield. In fact, global regulatory guidances treat packaging as a critical quality factor: FDA’s draft guidance emphasizes evaluating container closure systems for drug quality, and ICH explicitly requires stability studies on the drug in its final container–closure system.
Packaging that looks intact may still interact chemically or physically with the drug. For example, plasticizers or inks can migrate out of a film, or moisture can diffuse through a film and hydrolyze a moisture-sensitive API. Likewise, polyester or PVC films can develop static electricity as they unwind, causing tablets to stick or scatter, and poor film flow (high friction) can lead to tearing or misfeeds. These issues aren’t visible at a glance, so systematic evaluation is needed. Broadly speaking, compatibility covers two aspects: chemical/material interaction and physical handling performance. We’ll explain what each term means and how to assess it.
Drug–packaging compatibility refers to the mutual impact between the drug formulation and the packaging film. It’s not just about barrier performance (moisture or oxygen resistance), but about interaction: will anything leach out, and will the drug leave anything behind? Compatibility also includes processing behavior: can the film be formed, fed, and heat-sealed reliably with the given drug?
In practice, evaluating compatibility means answering: “Can this film keep the drug safe and run on our line?” The rest of this article walks through the four key risk areas.
Migration means that substances from the blister film migrate into the drug. Typical sources include polymer additives (plasticizers, stabilizers, slip agents), adhesives, printing inks, or coatings. Even monomer residues or catalysts can migrate. When in contact with the drug (especially if the lid is foil sealed directly to film or if there’s vapor space), these chemicals can leach into the tablets or capsules.
Regulators treat this under extractables & leachables (E&L). ICH’s emerging Q3E guidance and FDA draft guidance stress a risk-based framework for assessing E&L in packaging. In simple terms, migration risk depends on what chemicals are in the film and how harsh the contact conditions are (time, temperature). For example, oily APIs might draw out plasticizers, or moisture in a drug could dissolve film components.
A key distinction: Extractables are what you could pull out of packaging in laboratory solvents, while Leachables are what actually migrates under real storage/use conditions. Migration tests simulate worst-case conditions (e.g. high temp/humidity) and use analytical chemistry to detect any leachables in the product. But you don’t need to do blind screening without context – first conduct a risk assessment by reviewing the film’s composition. Get the material’s spec sheet or coextrusion recipe (often PVC/PVDC/PE layers, etc.), and ask suppliers for extractables data if available.
Practical tip: Suppose you use PVC/PVDC film. PVC may contain phthalate esters and residual vinyl chloride, while PVDC is often coated with organic solvents or plasticizers. Each layer could contribute migrants. So, risk assessment first: “Does this film or its ink have any known potential leachables?” If yes, plan targeted testing or choose a purer film. Remember: relying on the film’s trade name or type isn’t enough – the actual formulation (thickness, additives, sealant layers) matters.
In short, you must consider migration early. It’s not enough to pick a film because it’s “standard.” For example, PVC/PVDC films are common but have plasticizers that could migrate. So ask: What plasticizer is used, and what is its migration potential? For very sensitive drugs, you might instead choose a high-purity film (like COP/COP or laminated PCTFE) or even Alu-Alu foil to eliminate organic leachables.
Sorption covers the reverse concern: drug or excipient molecules transferring into the blister film. This usually happens by two mechanisms: absorption (penetrating into the bulk of the polymer) or adsorption (sticking onto the surface). Both can reduce the delivered dose or alter stability.
Drug sorption is often overlooked unless dealing with highly potent or sticky compounds. For example, lipophilic (greasy) APIs might dissolve slightly into a plasticizer-rich PVC layer. Or volatile actives could evaporate and be captured by a hydrophobic film. Typically, sorption is more a concern for compounds with affinity to polymers – think low-dose APIs, perfumes, or essential oils. Solid tablets usually have minimal direct contact, but fine powders can cling to surfaces.
Why it matters: If a small percentage of the API (or a critical excipient) is absorbed by the film, the content uniformity in the blister might fall out of spec over time. Also, the drug in the film may degrade or desorb later, causing stability surprises. In QC, a soaked-up API would show up as weight loss or lower assay in the tablet, and maybe residue on the film.
If sorption is significant, solutions include changing the film polymer, adding an inert barrier layer (like a thin PCTFE lining), or altering formulation (e.g. add a coating to the tablet to reduce sticking).
Thin plastic films rubbing against rollers, tanks, or other surfaces can easily build up static charge, especially under low-humidity conditions. In a blister line, the PVC or PET film sheet may become charged when unwound, cut, or thermoformed. Similarly, tablets sliding or tumbling generate their own charge. Static causes surprising problems in packaging:
Static is a process risk more than a chemical one, but it interacts with compatibility. For example, moisture lowers static (humid air allows charge to dissipate). But adding moisture to control static might worsen drug stability, so balance is needed.
Common static control methods:
Static effects are often visible as quality drops. If you see dust lumps on products or hear electric shocks when touching the film roll, investigate static control. Remember, this is not a chemical compatibility problem – but untreated static can mask or amplify real chemical issues, so it must be addressed in the overall assessment.
Friction is the mechanical resistance when the film moves against other surfaces (rollers, conveyors, tooling) or when tablets move within the cavities. Problems due to friction include:
While friction is often considered a mechanical issue, it does tie into compatibility: if the film tears or jams, production grinds to a halt. Ensuring the chosen film runs smoothly on your specific blister equipment is a form of “compatibility” with the manufacturing process.
Putting it all together, compatibility evaluation should follow a stepwise approach:
The idea is not to blindly test every combination, but to make smart choices. Regulatory guidance is clear that you don’t have to do every test on every new drug–package combination if risk is low, but you must justify skipping any test. In practice, doing some basic accelerated tests (even just a 3-month stability run in final packs) is common. It catches many issues early.
When choosing a specific blister film, weigh barrier needs against processing needs:
In all cases, don’t assume a film’s barrier rating (like an MVTR or OTR number) tells the whole story. Chemical compatibility is separate: a high-barrier film could still leach plasticizers, and a clear film might be tinted by an API over time. Balance all factors.
Image: A roll of transparent PVC blister film with formed cavities. When evaluating drug-blister compatibility, consider real examples: A commonly used PVC/PVDC film provides good moisture resistance but contains plasticizers that can migrate. A sophisticated PCTFE-lined film gives “virtually no water vapor penetration”, ideal for sensitive drugs, but costs more and requires lower-speed forming.
Finally, remember that material compatibility must be proven in the actual production setting. A film may pass lab tests but still fail under real machine conditions if not handled correctly. Key process factors include:
Figure: Jinlu Packing’s blister machines (e.g. model DPH-190Max) can handle a wide range of blister materials, from PVC and aluminum foil to PET and PS. They integrate precise forming, feeding and sealing controls to ensure consistent pack quality.
In short, run a full machine trial with the chosen film and product before scale-up. Observe the output packs for defects like incomplete fills, weak seals or foil damage. Only a hands-on trial can reveal issues like film slip or static that weren’t obvious in lab tests.
Being diligent pays off. Prevention of a quality issue in stability or production is far easier than troubleshooting a complaint or recall.
Drug Product–blister film compatibility is a cornerstone of pharmaceutical packaging design. It ensures that the blister film protects the medication without introducing new risks. By systematically evaluating migration, sorption, static, and friction risks – and by linking stability data to barrier choices – manufacturers can avoid nasty surprises later on. Always remember that a blister pack is part of the drug product, so packaging and formulation must be optimized together.
For each risk, use the right controls. Chemically, rely on compatibility testing and stability data. Physically, adjust humidity, use anti-static measures, and fine-tune machine settings. And remember: simulate real production. If a film spills out of the blister forming station or tablets bounce out of cavities on the first run, no lab test could have predicted that.
If you need help matching a drug to a blister film – or setting up your blister machine – Jinlu Packing’s experts are here to assist. We design blister lines that can accommodate all common film types (PVC/PVDC, PCTFE, Alu-Alu, etc.) while maintaining precise control of form and seal. Contact us to discuss your product requirements, or request a trial on one of our blister machines. With the right partnership and data, you can prevent compatibility surprises and keep production running smoothly.
It’s the ability of the blister film and drug product to coexist without adverse interactions. In practical terms, it means no unacceptable migration of film chemicals into the drug, no loss of drug into the film, and no processing problems (static, tearing) when packaging. It ensures the drug remains safe and effective while in that blister pack.
Migration usually comes from film additives (plasticizers, stabilizers) or inks leaching out. Factors like heat (during sealing or storage), moisture, and the drug’s properties (e.g. presence of solvents or oily components) can accelerate migration. For example, heat sealing at too high a temperature might drive more monomers out.
Extractables are chemicals that could be pulled out of a material under extreme conditions (like using strong solvents or high temp in a lab). Leachables are what actually migrate into the drug under normal or accelerated conditions. In packaging evaluation, you usually analyze extractables first to know what to look for, then check for leachables during stability or migration studies.
Consider the chemistry: is the drug oily or very hydrophobic? These tend to absorb into certain plastics. Also check if the drug dose is very low (micrograms); then even tiny sorption can matter. The best way is an empirical test: store product in the film and measure if potency drops more than expected degradation. Rinse and analyze the empty film for drug content as a check.
Static builds up when insulating films (like PVC, PET) move against surfaces (rollers, cutters) or when separated (e.g. unwinding a roll). In a dry environment or at high speed, the effect is stronger. Every time a tablet falls into a pocket, a tiny charge can form. Without neutralization, these charges accumulate.
Static-charged film can attract dust or fibers which then get sealed into the pack. It can cause tablets to misalign or “jump” during filling (leading to holes or double pills). Static during sealing can even crack tablets if a brush or sensor rubs against the charged surface. Overall, it tends to increase rejects and downtime if uncontrolled.
Film friction affects how the sheet moves. If the film sticks too much to a roller, it can break when the machine tries to pull more. If it slips unpredictably, seal alignment can be off. Rough spots on film can mar tablets. High friction on a detents wheel can crunch film edges. So matching the film’s surface properties and tension to the machine is key.
Start small. Do lab tests on packaged mini-blisters or individual tablets sealed under lab conditions. Use accelerated aging (high temp/humidity) to “speed up” effects. Run a short engineering batch on the actual machine (with sampling) to watch for static or feed issues. Analytical assays can then reveal any migration or potency changes early on.
The considerations are similar, but note that capsules (with smooth shells) may slide differently in cavities than flat tablets. You may need slightly higher friction to hold capsules or a shallower depth. For high-barrier needs, both forms can use the same film stacks (PVC/PVDC, PCTFE, Alu-Alu, etc.). The key is matching barrier to sensitivity: moisture-sensitive capsules or coated tablets often use the same high-barrier films.
References：
1.Container Closure Systems for Human Drugs and Biological Products —— FDA
2.GUIDELINE FOR EXTRACTABLES AND LEACHABLES —— ICH Q3E
3.Understanding and Characterizing the Drug Sorption to PVC and PE Materials —— PubMed
4.Comparison of solute-binding properties of plastic materials used as pharmaceutical product containers —— PubMed
5.Impact of electrostatics on processing and product performance of pharmaceutical solids —— Monash University
6.Standard Test Method for Determining Integrity of Primary Packaging by Visual Inspection —— ASTM F1886/F1886M-25
Petty Fu, Founder of Jinlupacking, brings over 20 years of expertise to the pharmaceutical machinery sector. Under his leadership, Jinlu has grown into a trusted supplier integrating design, production, and sales. Petty is passionate about sharing his deep industry knowledge to help clients navigate the complexities of pharma packaging, ensuring they receive not just equipment, but a true one-stop service partnership tailored to their production goals.
